Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Rating of “Hold” from Brokerages

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have been given a consensus rating of “Hold” by the five research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $32.00.

FLGT has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Finally, Wall Street Zen lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th.

Fulgent Genetics Price Performance

Shares of NASDAQ FLGT opened at $15.59 on Friday. Fulgent Genetics has a 1 year low of $13.46 and a 1 year high of $31.04. The company’s 50-day moving average is $20.84 and its 200 day moving average is $23.92. The stock has a market capitalization of $486.89 million, a P/E ratio of -7.95 and a beta of 0.94.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Friday, February 27th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.02 by $0.14. The business had revenue of $83.34 million during the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Research analysts anticipate that Fulgent Genetics will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Fulgent Genetics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. grew its stake in shares of Fulgent Genetics by 2,984,354.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after buying an additional 1,522,021 shares during the last quarter. Millennium Management LLC raised its stake in Fulgent Genetics by 1.8% during the third quarter. Millennium Management LLC now owns 1,468,844 shares of the company’s stock valued at $33,196,000 after buying an additional 26,582 shares during the last quarter. Vanguard Group Inc. raised its stake in Fulgent Genetics by 1.1% during the third quarter. Vanguard Group Inc. now owns 1,179,254 shares of the company’s stock valued at $26,651,000 after buying an additional 13,295 shares during the last quarter. RTW Investments LP purchased a new stake in shares of Fulgent Genetics in the fourth quarter worth $18,521,000. Finally, Geode Capital Management LLC increased its holdings in shares of Fulgent Genetics by 1.6% during the second quarter. Geode Capital Management LLC now owns 513,343 shares of the company’s stock valued at $10,207,000 after acquiring an additional 8,105 shares in the last quarter. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.